LUMO News and Press, Lumos Pharma Inc. From 08/05/21

• Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progre...

AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, David B. Karpf, MD, joined the Company August 3, ...

AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew, PhD, was promoted to Pres...

AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Company’s Clinical Scientific Advisory B...

AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2021 financial results before market open on Thursday, August 5, 202...

primeimages/E+ via Getty Images Wall Street continued to shake off recent COVID fears on Wednesday. A growing sense that the Delta variant won't force a renewed closure of the economy has given fresh strength to reopening stocks. This dynamic prompted a substantial rally in cruise companies o...

Gainers: [[ASPU]] +6.9%. [[SDC]] +4.9%. [[XM]] +4.5%. [[AFIB]] +4.3%. [[NERV]] +4.0%.Losers: [[SNBR]] -10.2%. [[LUMO]] -9.3%. [[KRUS]] -8.3%. [[ALLO]] -5.0%. [[SYBX]] -4.8%. For further details see: ASPU, AFIB, SNBR and LUMO among after-hours movers

OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 months OraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be extended to 12 months with primary data at 6-months Cash balance ...

Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels AUSTIN, Texas, June 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical...

AUSTIN, Texas, May 19, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on J...